Shares of Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $25.69.
A number of equities research analysts have weighed in on the stock. Morgan Stanley set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Citizens Jmp restated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a report on Monday, August 24th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Monday, August 24th. JPMorgan Chase & Co. assumed coverage on shares of Kura Oncology in a research report on Thursday, October 1st. They set an “overweight” rating and a $30.00 price objective for the company. Finally, Wedbush lifted their target price on shares of Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Thursday, August 13th.
Read Our Latest Report on Kura Oncology
Kura Oncology Price Performance
Kura Oncology (NASDAQ:KURA – Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.11. The business had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. As a group, sell-side analysts forecast that Kura Oncology will post -3.25 earnings per share for the current fiscal year.
Insider Activity at Kura Oncology
In other news, insider Mollie Leoni sold 28,802 shares of Kura Oncology stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $10.75, for a total value of $309,621.50. Following the completion of the sale, the insider directly owned 141,095 shares of the company’s stock, valued at approximately $1,516,771.25. The trade was a 16.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Teresa Bair sold 31,487 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $12.63, for a total value of $397,680.81. Following the completion of the sale, the insider owned 195,444 shares in the company, valued at $2,468,457.72. This represents a 13.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 153,881 shares of company stock valued at $1,708,183 over the last ninety days. 7.60% of the stock is owned by insiders.
Hedge Funds Weigh In On Kura Oncology
A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. IFP Advisors Inc raised its holdings in Kura Oncology by 136.5% during the second quarter. IFP Advisors Inc now owns 2,542 shares of the company’s stock worth $28,000 after purchasing an additional 1,467 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in Kura Oncology by 11.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 23,297 shares of the company’s stock worth $194,000 after purchasing an additional 2,304 shares in the last quarter. WINTON GROUP Ltd boosted its position in Kura Oncology by 26.2% during the second quarter. WINTON GROUP Ltd now owns 13,000 shares of the company’s stock worth $143,000 after purchasing an additional 2,700 shares in the last quarter. Hsbc Holdings PLC boosted its position in Kura Oncology by 6.5% during the second quarter. Hsbc Holdings PLC now owns 94,810 shares of the company’s stock worth $1,055,000 after purchasing an additional 5,778 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in Kura Oncology by 148.4% in the second quarter. Allworth Financial LP now owns 10,326 shares of the company’s stock valued at $113,000 after purchasing an additional 6,169 shares during the last quarter.
Kura Oncology Company Profile
Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company uses molecular and genomic insights to identify therapies designed to target specific biological drivers of tumor growth.
Kura’s lead program is ziftomenib, an oral menin inhibitor developed for genetically defined forms of acute myeloid leukemia, including disease associated with NPM1 mutations and KMT2A rearrangements. The company has also evaluated additional targeted oncology candidates, including therapies directed at the RAF-MEK-ERK signaling pathway.
Founded in 2014 and headquartered in San Diego, California, Kura has conducted clinical development activities through research collaborations and studies involving patients and institutions in the United States and other regions.
Featured Articles
- Five stocks we like better than Kura Oncology
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}